Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor.

PLoS One · 2023 · PMC10266688 · PMID 37315065

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Up284 significantly reduced tumor burden (p = 0.002) and showed a trend for prolonged survival compared to vehicle treated group (p = 0.06) ( Fig 6D–6F ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.